Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

bout Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 study. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Dow Jones Sustainability Indexes for Six Consecutive Years... -- ABBOTT PARK, Ill., Sept. 9 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... Pharmaceuticals, LLC announced today the approval of a new, ... 0.0375%, for the treatment of acne vulgaris. An excellent ... between strength – effective yet gentle. Tretin-X 0.0375% ... those patients already on tretinoin therapy for acne, Tretin-X ...
Cached Medicine Technology:Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 2Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 3Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 4Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 5Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 6Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 7Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years in Recognition of Leading Corporate Citizenship Performance 8New, Exclusive Strength: Tretin-X® 0.0375%(tretinoin) Cream 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 Volunteers from ... against drug abuse this week with drug education lectures, ... education booklet distribution in cities around the world. , ... U.S. National Institute on Drug Abuse, abuse of alcohol ... annually in crime, lost work, decreased productivity and healthcare. ...
(Date:7/11/2014)... Well Intervention Market report defines and segments the well intervention ... well intervention services market in Europe is estimated to grow ... 2018, at a CAGR of 7% from 2013 to 2018. ... Market report, to get an idea of the in-depth analysis ... the Europe well intervention market, and is supported by various ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- In people with ... are similar to that seen in drug addicts as ... are clear differences in brain activity between patients who ... mirror those of drug addicts," study author Dr. Valerie ... in a university news release. Voon,s research involved ...
(Date:7/11/2014)... 2014 The report “Probiotics Market ... Animal Feed), Applications (Regular, Therapeutic, Preventive Health Care) ... & Forecasts to 2019 ” defines and segments ... forecasting of the market value of probiotic products ... and restraining factors for the global market with ...
(Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... , PHILADELPHIA, Dec. 2 Independence ... with Lincoln Financial Group. IBC will be the primary provider ... retirees, and their dependents across the nation. The Lincoln plan ... plans. , "I know I speak for all of us ...
... who have a prostate-specific antigen (PSA) value of less ... external beam radiation therapy (EBRT) are less likely to ... a study in the December 1 issue of the ... the American Society for Radiation Oncology (ASTRO). PSA levels ...
... ... microwave signal transmissions away from users will be available in early 2010 from Aerius ... ... transmissions away from users will be available in early 2010 from Aerius International Ltd. ...
... , ATLANTA, Dec. 2 In response ... FamilyLife, a non-profit ministry dedicated to supporting marriages and families, ... at a significant discount to military couples in Atlanta from ... Buckhead (3300 Peachtree Road NE). Weekend to Remember ...
... /PRNewswire/ -- The Universities of Sassari and Cagliari ... from the United States, announced today the results of a ... amounts of CLA (Conjugated Linoleic Acid), an Omega-6 polyunsaturated fatty ... bioactive properties for humans. , The study, conducted ...
... when women at high-risk of breast cancer are well-informed about ... prevention, only 6 percent said they were likely to take ... Center created a decision aid designed to inform women about ... was first used to stop breast cancer from returning and ...
Cached Medicine News:Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 2Health News:New Study Confirms Health Benefits of Pecorino Romano Cheese 3Health News:High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: